Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Fallers
Mayne Pharma (ASX:MYX) share price lower despite positive updates
Broker Notes
Leading brokers name 3 ASX shares to sell today
Share Fallers
Why GPT, Mayne Pharma, Talga, & Zip shares are tumbling lower
52-Week Highs
These 3 ASX shares have just hit 52-week highs or better
Share Gainers
Why Eagers Auto, Mayne Pharma, Monadelphous, & Newcrest are pushing higher
Share Gainers
Here's why the Mayne Pharma (ASX:MYX) share price is shooting 28% higher
Share Market News
Why the Mayne Pharma (ASX:MYX) share price is dropping 5% today
Share Gainers
Why the Mayne Pharma (ASX:MYX) share price is pushing higher
Share Market News
Which ASX shares will China 'punish' next?
Healthcare Shares
2 ASX healthcare shares that have risen since Pfizer's vaccine news
Share Market News
Mayne Pharma (ASX:MYX) share price dives 16% on FDA update
Share Fallers
Why IAG, Mayne Pharma, Mesoblast, & Temple & Webster shares are tumbling lower
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
